Holding Lumakras (Sotorasib) Prior to Surgery
There are no specific evidence-based guidelines for holding Lumakras (sotorasib) before surgical procedures. However, based on the drug's pharmacokinetic properties and general perioperative principles for oral anticancer agents, a reasonable approach can be extrapolated.
Recommended Approach
Preoperative Management
For low bleeding risk procedures:
- Hold Lumakras for 24 hours before the procedure (skip 1 dose)
- This allows approximately 1-2 half-lives to elapse, reducing drug levels while maintaining some therapeutic effect
For high bleeding risk procedures:
- Hold Lumakras for 48-72 hours before the procedure (skip 2-3 doses)
- This allows approximately 3-4 half-lives to elapse, minimizing drug-related bleeding risk
Rationale
Sotorasib has an elimination half-life of approximately 24 hours 1. The drug is taken once daily at 960 mg. While there are no published studies specifically addressing perioperative management of sotorasib, the general principles used for other oral targeted therapies can be applied.
The FDA label for Lumakras does not provide specific perioperative guidance 1. However, the drug's pharmacokinetic profile suggests that holding for 1-2 days (low-risk procedures) to 2-3 days (high-risk procedures) would allow adequate drug clearance.
Classification of Surgical Risk
Low bleeding risk procedures include:
- Dental extractions (1-3 teeth)
- Superficial dermatologic procedures
- Endoscopy without biopsy
- Cataract surgery
- Minor biopsies 2
High bleeding risk procedures include:
- Major abdominal surgery
- Intracranial or spinal surgery
- Major orthopedic surgery
- Procedures requiring neuraxial anesthesia
- Extensive tissue dissection 3, 4
Postoperative Resumption
Resume Lumakras when:
- At least 24 hours have elapsed after low bleeding risk procedures
- At least 48-72 hours have elapsed after high bleeding risk procedures
- Adequate hemostasis has been achieved
- No ongoing bleeding complications
- Patient can tolerate oral medications 1
Important Considerations
Hepatotoxicity monitoring: Sotorasib carries a significant risk of hepatotoxicity (10-15% grade 3-4) 1, 5. The perioperative period may compound this risk, particularly if patients receive other hepatotoxic medications or experience surgical stress. Monitor liver function tests closely when resuming therapy.
Drug interactions: Avoid proton pump inhibitors (PPIs) and H2 receptor antagonists during the perioperative period, as these significantly reduce sotorasib absorption 1. If acid suppression is necessary, use locally acting antacids administered 4 hours before or 10 hours after sotorasib.
No bridging required: Unlike anticoagulants, there is no need for "bridging" therapy during the interruption period. The oncologic risk of brief treatment interruption (2-3 days) is minimal compared to potential surgical complications.
Clinical Pitfalls to Avoid
Do not continue sotorasib through major surgery without discussing with the surgical team, as the drug may theoretically impair wound healing (though this is not well-documented)
Do not resume too early after high-risk procedures, as adequate wound healing takes precedence over immediate cancer therapy resumption
Coordinate with oncology before holding therapy for more than 3-4 days, particularly in patients with rapidly progressive disease
Document the plan clearly in the medical record, including the date/time of last dose and planned resumption
Special Populations
Patients with hepatic impairment: Consider longer interruption periods, as drug clearance may be delayed. No specific dosing adjustments are provided in the label, but clinical judgment suggests extending the hold period by 24 hours 1.
Patients with renal impairment: Sotorasib is not primarily renally cleared, so standard timing applies 1.
Emergency surgery: If emergency surgery is required and the patient recently took sotorasib, proceed with surgery as clinically indicated. The drug's half-life of 24 hours means significant clearance occurs within 48 hours, but emergency situations take precedence over optimal drug timing.